Browse by category

Fractyl Health has announced positive one-year results from its REMAIN-1 Midpoint Cohort, reinforcing the potential of the Revita DMR System (Revita) to be the first durable procedural therapy for post-GLP-1 weight maintenance. The key findings include: Dose-dependent durability confirmed at one year: In the full modified intention-to-treat (mITT) population (N=45), a single Revita procedure reduced weight regain by approximately 40% versus sham at one year (least-squares mea

An outpatient procedure may offer a way for the estimated 70% of people who discontinue popular weight-loss drugs to avoid regaining weight, according to a study, ‘Duodenal mucosal resurfacing prevents weight regain after tirzepatide withdrawal: REMAIN-1 multicenter, randomized, double-blind, sham-controlled clinical trial—midpoint cohort results’, presented at Digestive Disease Week 2026. Nearly one in five adults with obesity have taken a glucagon-like peptide-1 (GLP-1), an

A Cleveland Clinic analysis of nearly 8,000 patients suggests that discontinuing semaglutide and tirzepatide, on average, does not lead to significant weight regain in clinical practice, as many patients later restart the original medication or try an alternative obesity treatment. In one of the largest real-world studies to date examining obesity treatment use and long-term weight changes after GLP-1 discontinuation, researchers at Cleveland Clinic found that many patients s

Fractyl Health has announced positive early data from the open-label REVEAL-1 cohort of its ongoing REMAIN-1 pivotal study. The results...